UniPharma Co., Ltd. (TPEX:6621)

Taiwan · Delayed Price · Currency is TWD

11.65

+0.30 (2.64%)

Aug 19, 2026, 9:17 AM CST

-8.63% (1Y)

Market Cap	410.04M -9.4%
Revenue (ttm)	83.87M -5.4%
Net Income	-40.10M
EPS	-1.13
Shares Out	35.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,001
Open	11.65
Previous Close	11.35
Day's Range	11.65 - 11.65
52-Week Range	10.60 - 16.00
Beta	-0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About UniPharma

UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services. It serves m... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1998

Employees 34

Stock Exchange Taipei Exchange

Ticker Symbol 6621

Full Company Profile

Financial Performance

In 2025, UniPharma's revenue was 88.44 million, a decrease of -5.36% compared to the previous year's 93.46 million. Losses were -40.54 million, 63.4% more than in 2024.

Financial Statements